Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) is common worldwide. The importance of genetic and epigen- eric changes in etiology and pathogenesis of NAFLD has been increasingly recognized. However, the ex- act mechanism is largely unknown. A large number of single nucleotide polymorphisms (SNPs) related...
Saved in:
Published in | World journal of gastroenterology : WJG Vol. 18; no. 45; pp. 6546 - 6551 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
United States
Baishideng Publishing Group Co., Limited
07.12.2012
|
Subjects | |
Online Access | Get full text |
ISSN | 1007-9327 2219-2840 2219-2840 |
DOI | 10.3748/wjg.v18.i45.6546 |
Cover
Abstract | Nonalcoholic fatty liver disease (NAFLD) is common worldwide. The importance of genetic and epigen- eric changes in etiology and pathogenesis of NAFLD has been increasingly recognized. However, the ex- act mechanism is largely unknown. A large number of single nucleotide polymorphisms (SNPs) related to NAFLD has been documented by candidate gene studies (CGSs). Among these genes, peroxisome pro- liferatoractivated receptor-γ, adiponectin, leptin and tumor necrosis factor-α were frequently reported. Since the introduction of genome-wide association studies (GWASs), there have been significant advances in our understanding of genomic variations of NAFLD. Patatin- like phospholipase domain containing family member A3 (PNPLA3, SNP rs738409, encoding I148M), also termed adiponutrin, has caught most attention. The evidence that PNPLA3 is associated with increased hepatic fat levels and hepatic inflammation has been validated by a series of studies. Epigenetic modification refers to phenotypic changes caused by an adaptive mechanism unrelated to alteration of primary DNA se- quences. Epigenetic regulation mainly includes microR- NAs (miRs), DNA methylation, histone modifications and ubiquitination, among which miRs are studied most extensively, miRs are small natural single stranded RNA molecules regulating mRNA degradation or translation inhibition, subsequently altering protein expression of target genes. The miR-122, a highly abundant miR ac- counting for nearly 70% of all miRs in the liver, is sig- nificantly under-expressed in NAFLD subjects. Inhibition of miR-122 with an antisense oligonucleotide results in decreased mRNA expression of lipogenJc genes and improvement of liver steatosis. The investigation into epigenetic involvement in NAFLD pathogenesis is just at the beginning and needs to be refined. This review summarizes the roles of genetics and epigenetics in the development of NAFLD. The progress made in this field may provide novel diagnostic biomarkers and therapeu- tic targets for NAFLD management. |
---|---|
AbstractList | Nonalcoholic fatty liver disease (NAFLD) is common worldwide. The importance of genetic and epigen- eric changes in etiology and pathogenesis of NAFLD has been increasingly recognized. However, the ex- act mechanism is largely unknown. A large number of single nucleotide polymorphisms (SNPs) related to NAFLD has been documented by candidate gene studies (CGSs). Among these genes, peroxisome pro- liferatoractivated receptor-γ, adiponectin, leptin and tumor necrosis factor-α were frequently reported. Since the introduction of genome-wide association studies (GWASs), there have been significant advances in our understanding of genomic variations of NAFLD. Patatin- like phospholipase domain containing family member A3 (PNPLA3, SNP rs738409, encoding I148M), also termed adiponutrin, has caught most attention. The evidence that PNPLA3 is associated with increased hepatic fat levels and hepatic inflammation has been validated by a series of studies. Epigenetic modification refers to phenotypic changes caused by an adaptive mechanism unrelated to alteration of primary DNA se- quences. Epigenetic regulation mainly includes microR- NAs (miRs), DNA methylation, histone modifications and ubiquitination, among which miRs are studied most extensively, miRs are small natural single stranded RNA molecules regulating mRNA degradation or translation inhibition, subsequently altering protein expression of target genes. The miR-122, a highly abundant miR ac- counting for nearly 70% of all miRs in the liver, is sig- nificantly under-expressed in NAFLD subjects. Inhibition of miR-122 with an antisense oligonucleotide results in decreased mRNA expression of lipogenJc genes and improvement of liver steatosis. The investigation into epigenetic involvement in NAFLD pathogenesis is just at the beginning and needs to be refined. This review summarizes the roles of genetics and epigenetics in the development of NAFLD. The progress made in this field may provide novel diagnostic biomarkers and therapeu- tic targets for NAFLD management. Nonalcoholic fatty liver disease (NAFLD) is common worldwide. The importance of genetic and epigenetic changes in etiology and pathogenesis of NAFLD has been increasingly recognized. However, the exact mechanism is largely unknown. A large number of single nucleotide polymorphisms (SNPs) related to NAFLD has been documented by candidate gene studies (CGSs). Among these genes, peroxisome proliferatoractivated receptor-γ, adiponectin, leptin and tumor necrosis factor-α were frequently reported. Since the introduction of genome-wide association studies (GWASs), there have been significant advances in our understanding of genomic variations of NAFLD. Patatin-like phospholipase domain containing family member A3 (PNPLA3, SNP rs738409, encoding I148M), also termed adiponutrin, has caught most attention. The evidence that PNPLA3 is associated with increased hepatic fat levels and hepatic inflammation has been validated by a series of studies. Epigenetic modification refers to phenotypic changes caused by an adaptive mechanism unrelated to alteration of primary DNA sequences. Epigenetic regulation mainly includes microRNAs (miRs), DNA methylation, histone modifications and ubiquitination, among which miRs are studied most extensively. miRs are small natural single stranded RNA molecules regulating mRNA degradation or translation inhibition, subsequently altering protein expression of target genes. The miR-122, a highly abundant miR accounting for nearly 70% of all miRs in the liver, is significantly under-expressed in NAFLD subjects. Inhibition of miR-122 with an antisense oligonucleotide results in decreased mRNA expression of lipogenic genes and improvement of liver steatosis. The investigation into epigenetic involvement in NAFLD pathogenesis is just at the beginning and needs to be refined. This review summarizes the roles of genetics and epigenetics in the development of NAFLD. The progress made in this field may provide novel diagnostic biomarkers and therapeutic targets for NAFLD management. Nonalcoholic fatty liver disease (NAFLD) is common worldwide. The importance of genetic and epigenetic changes in etiology and pathogenesis of NAFLD has been increasingly recognized. However, the exact mechanism is largely unknown. A large number of single nucleotide polymorphisms (SNPs) related to NAFLD has been documented by candidate gene studies (CGSs). Among these genes, peroxisome proliferatoractivated receptor-γ, adiponectin, leptin and tumor necrosis factor-α were frequently reported. Since the introduction of genome-wide association studies (GWASs), there have been significant advances in our understanding of genomic variations of NAFLD. Patatin-like phospholipase domain containing family member A3 (PNPLA3, SNP rs738409, encoding I148M), also termed adiponutrin, has caught most attention. The evidence that PNPLA3 is associated with increased hepatic fat levels and hepatic inflammation has been validated by a series of studies. Epigenetic modification refers to phenotypic changes caused by an adaptive mechanism unrelated to alteration of primary DNA sequences. Epigenetic regulation mainly includes microRNAs (miRs), DNA methylation, histone modifications and ubiquitination, among which miRs are studied most extensively. miRs are small natural single stranded RNA molecules regulating mRNA degradation or translation inhibition, subsequently altering protein expression of target genes. The miR-122, a highly abundant miR accounting for nearly 70% of all miRs in the liver, is significantly under-expressed in NAFLD subjects. Inhibition of miR-122 with an antisense oligonucleotide results in decreased mRNA expression of lipogenic genes and improvement of liver steatosis. The investigation into epigenetic involvement in NAFLD pathogenesis is just at the beginning and needs to be refined. This review summarizes the roles of genetics and epigenetics in the development of NAFLD. The progress made in this field may provide novel diagnostic biomarkers and therapeutic targets for NAFLD management.Nonalcoholic fatty liver disease (NAFLD) is common worldwide. The importance of genetic and epigenetic changes in etiology and pathogenesis of NAFLD has been increasingly recognized. However, the exact mechanism is largely unknown. A large number of single nucleotide polymorphisms (SNPs) related to NAFLD has been documented by candidate gene studies (CGSs). Among these genes, peroxisome proliferatoractivated receptor-γ, adiponectin, leptin and tumor necrosis factor-α were frequently reported. Since the introduction of genome-wide association studies (GWASs), there have been significant advances in our understanding of genomic variations of NAFLD. Patatin-like phospholipase domain containing family member A3 (PNPLA3, SNP rs738409, encoding I148M), also termed adiponutrin, has caught most attention. The evidence that PNPLA3 is associated with increased hepatic fat levels and hepatic inflammation has been validated by a series of studies. Epigenetic modification refers to phenotypic changes caused by an adaptive mechanism unrelated to alteration of primary DNA sequences. Epigenetic regulation mainly includes microRNAs (miRs), DNA methylation, histone modifications and ubiquitination, among which miRs are studied most extensively. miRs are small natural single stranded RNA molecules regulating mRNA degradation or translation inhibition, subsequently altering protein expression of target genes. The miR-122, a highly abundant miR accounting for nearly 70% of all miRs in the liver, is significantly under-expressed in NAFLD subjects. Inhibition of miR-122 with an antisense oligonucleotide results in decreased mRNA expression of lipogenic genes and improvement of liver steatosis. The investigation into epigenetic involvement in NAFLD pathogenesis is just at the beginning and needs to be refined. This review summarizes the roles of genetics and epigenetics in the development of NAFLD. The progress made in this field may provide novel diagnostic biomarkers and therapeutic targets for NAFLD management. |
Author | Yu-Yuan Li |
AuthorAffiliation | Department of Gastroenterology and Hepatology, Guangzhou Institute of Clinical Research, Guangzhou First Municipal People's Hospital, Guangzhou Medical College, Guangzhou 510180, Guangdong Province, China |
Author_xml | – sequence: 1 givenname: Yu-Yuan surname: Li fullname: Li, Yu-Yuan |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23236228$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kU1rFDEcxoNU7Lb17knirZdZ8zaZzEWQUqtQ8GLPIZP8ZzYlm2wn2ZF-e7N0XdSDpxDyvJHfBTqLKQJC7yhZ806ojz8fp_VC1dqLdi1bIV-hFWO0b5gS5AytKCFd03PWnaOLnB8JYZy37A06Z5xxyZhaIX0HEYq32ESHYeen43UxszexZOzjGPYQrY8TLhvADhYIabeFWHAacR1kgk2bFKppNKU84-AXmLHzGUyGK_R6NCHD2-N5iR6-3P64-drcf7_7dvP5vrFCqdJIapVwPXVuGEc6QjsOghHay56qgVJHORuMGVxHKbFGDkoBqJ4brkRnoTX8En16yd3thy04W-fNJujd7LdmftbJeP33S_QbPaVF85ZKRmQNuD4GzOlpD7norc8WQjAR0j5rynhP2q7rVZW-_7PrVPL7V6uAvAjsnHKeYTxJKNEHcLqC0xWcruD0AVy1yH8s1hdTfDqs9eF_xg9H4ybF6aliOpUJIQhRkvFffH6tRQ |
CitedBy_id | crossref_primary_10_3390_ijms16035161 crossref_primary_10_1002_hep_27131 crossref_primary_10_1002_stem_2231 crossref_primary_10_3390_life12060790 crossref_primary_10_3390_nu6083303 crossref_primary_10_1016_j_lfs_2024_122806 crossref_primary_10_4254_wjh_v7_i24_2497 crossref_primary_10_1080_17474124_2020_1736042 crossref_primary_10_3748_wjg_v28_i25_2937 crossref_primary_10_1111_1440_1681_12940 crossref_primary_10_1111_1751_2980_12610 crossref_primary_10_1016_j_cca_2015_05_002 crossref_primary_10_14218_JCTH_2021_00067 crossref_primary_10_3389_fimmu_2022_921765 crossref_primary_10_1016_j_mam_2016_11_008 crossref_primary_10_1152_physiolgenomics_00023_2015 crossref_primary_10_1007_s11901_017_0372_8 crossref_primary_10_1016_j_plefa_2015_04_007 crossref_primary_10_1111_eci_12899 crossref_primary_10_1111_ijpo_234 crossref_primary_10_1016_j_heliyon_2022_e11119 crossref_primary_10_1016_j_hpb_2020_07_011 crossref_primary_10_3748_wjg_v21_i41_11552 crossref_primary_10_1007_s10620_016_4120_7 crossref_primary_10_1186_s41021_022_00246_1 crossref_primary_10_4254_wjh_v6_i8_613 crossref_primary_10_1016_j_gene_2015_09_007 crossref_primary_10_1016_j_jcmgh_2015_05_006 crossref_primary_10_1371_journal_pone_0071391 crossref_primary_10_1186_s12876_016_0557_6 crossref_primary_10_1007_s12072_016_9729_2 crossref_primary_10_2217_epi_2022_0362 crossref_primary_10_1016_j_jaad_2013_10_044 crossref_primary_10_3892_mco_2013_148 crossref_primary_10_1186_s12944_019_1001_z crossref_primary_10_3109_1354750X_2014_958535 crossref_primary_10_1016_j_metabol_2014_06_016 crossref_primary_10_1111_jdi_12792 crossref_primary_10_1186_s12933_015_0222_3 crossref_primary_10_1155_2018_8635329 crossref_primary_10_3390_nu13051679 crossref_primary_10_1016_j_jnutbio_2013_11_007 crossref_primary_10_3390_jcm5050052 crossref_primary_10_1016_j_ygeno_2013_03_007 crossref_primary_10_1152_ajpgi_00079_2013 crossref_primary_10_3748_wjg_v20_i40_14706 crossref_primary_10_1038_srep23709 crossref_primary_10_1017_S2040174420000124 crossref_primary_10_1186_s12951_018_0391_9 crossref_primary_10_3748_wjg_v21_i4_1099 crossref_primary_10_1016_j_metabol_2015_12_012 crossref_primary_10_1097_MPG_0000000000001053 crossref_primary_10_1136_gutjnl_2015_309456 |
ContentType | Journal Article |
Copyright | 2012 Baishideng Publishing Group Co., Limited. All rights reserved. 2012 |
Copyright_xml | – notice: 2012 Baishideng Publishing Group Co., Limited. All rights reserved. 2012 |
DBID | 2RA 92L CQIGP W91 ~WA AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
DOI | 10.3748/wjg.v18.i45.6546 |
DatabaseName | 维普_期刊 中文科技期刊数据库-CALIS站点 维普中文期刊数据库 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
DocumentTitleAlternate | Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease |
EISSN | 2219-2840 |
EndPage | 6551 |
ExternalDocumentID | PMC3516206 23236228 10_3748_wjg_v18_i45_6546 44400862 |
Genre | Research Support, Non-U.S. Gov't Journal Article Review |
GroupedDBID | --- 123 29R 2B. 2C~ 2RA 2WC 36B 53G 5VR 8WL 92F 92I 92L 93N 93R AAKDD ACGFO AENEX AFUIB ALMA_UNASSIGNED_HOLDINGS CCEZO CHBEP CIEJG CQIGP CS3 CW9 DIK DU5 E3Z EBS EJD EMB F5P FA0 FRP GX1 HYE M~E OK1 P2P RNS RPM SV3 TCJ TGQ TR2 W91 WFFXF XSB ~WA AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
ID | FETCH-LOGICAL-c488t-61c84d91ddbff1fe5fb420196918b11d132baabd7110ca6b88ee893a3847ce5a3 |
ISSN | 1007-9327 2219-2840 |
IngestDate | Thu Aug 21 18:21:18 EDT 2025 Fri Jul 11 15:32:42 EDT 2025 Mon Jul 21 05:39:05 EDT 2025 Tue Jul 01 03:21:57 EDT 2025 Thu Apr 24 23:00:00 EDT 2025 Wed Feb 14 10:44:49 EST 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 45 |
Keywords | Nonalcoholic fatty liver disease MicroRNA Epigenetic Methylation |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c488t-61c84d91ddbff1fe5fb420196918b11d132baabd7110ca6b88ee893a3847ce5a3 |
Notes | 14-1219/R Nonalcoholic fatty liver disease (NAFLD) is common worldwide. The importance of genetic and epigen- eric changes in etiology and pathogenesis of NAFLD has been increasingly recognized. However, the ex- act mechanism is largely unknown. A large number of single nucleotide polymorphisms (SNPs) related to NAFLD has been documented by candidate gene studies (CGSs). Among these genes, peroxisome pro- liferatoractivated receptor-γ, adiponectin, leptin and tumor necrosis factor-α were frequently reported. Since the introduction of genome-wide association studies (GWASs), there have been significant advances in our understanding of genomic variations of NAFLD. Patatin- like phospholipase domain containing family member A3 (PNPLA3, SNP rs738409, encoding I148M), also termed adiponutrin, has caught most attention. The evidence that PNPLA3 is associated with increased hepatic fat levels and hepatic inflammation has been validated by a series of studies. Epigenetic modification refers to phenotypic changes caused by an adaptive mechanism unrelated to alteration of primary DNA se- quences. Epigenetic regulation mainly includes microR- NAs (miRs), DNA methylation, histone modifications and ubiquitination, among which miRs are studied most extensively, miRs are small natural single stranded RNA molecules regulating mRNA degradation or translation inhibition, subsequently altering protein expression of target genes. The miR-122, a highly abundant miR ac- counting for nearly 70% of all miRs in the liver, is sig- nificantly under-expressed in NAFLD subjects. Inhibition of miR-122 with an antisense oligonucleotide results in decreased mRNA expression of lipogenJc genes and improvement of liver steatosis. The investigation into epigenetic involvement in NAFLD pathogenesis is just at the beginning and needs to be refined. This review summarizes the roles of genetics and epigenetics in the development of NAFLD. The progress made in this field may provide novel diagnostic biomarkers and therapeu- tic targets for NAFLD management. Nonalcoholic fatty liver disease; Epigenetic;MicroRNA; Methylation ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 Author contributions: Li YY solely contributed to this paper. Telephone: +86-20-81048720 Fax: +86-20-81045937 Correspondence to: Yu-Yuan Li, Professor, Department of Gastroenterology and Hepatology, Guangzhou Institute of Clinical Research, Guangzhou First Municipal People’s Hospital, Guangzhou Medical College, Guangzhou 510180, Guangdong Province, China. liyyliyy@tom.com |
OpenAccessLink | https://www.wjgnet.com/1007-9327/full/v18/i45/6546.htm |
PMID | 23236228 |
PQID | 1239057798 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3516206 proquest_miscellaneous_1239057798 pubmed_primary_23236228 crossref_primary_10_3748_wjg_v18_i45_6546 crossref_citationtrail_10_3748_wjg_v18_i45_6546 chongqing_primary_44400862 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2012-12-07 |
PublicationDateYYYYMMDD | 2012-12-07 |
PublicationDate_xml | – month: 12 year: 2012 text: 2012-12-07 day: 07 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | World journal of gastroenterology : WJG |
PublicationTitleAlternate | World Journal of Gastroenterology |
PublicationYear | 2012 |
Publisher | Baishideng Publishing Group Co., Limited |
Publisher_xml | – name: Baishideng Publishing Group Co., Limited |
References | 21381068 - Hepatology. 2011 Jun;53(6):1883-94 20473581 - Obes Surg. 2010 Dec;20(12):1698-709 20803499 - Hepatology. 2010 Oct;52(4):1281-90 21633658 - World J Gastroenterol. 2011 May 28;17(20):2536-42 19914930 - QJM. 2010 Feb;103(2):71-83 15464424 - Mol Genet Metab. 2004 Sep-Oct;83(1-2):93-102 22093607 - Gastroenterol Hepatol. 2012 Jan;35(1):32-41 18710329 - Metab Syndr Relat Disord. 2008 Sep;6(3):209-14 21037258 - Nucleic Acids Res. 2011 Jan;39(Database issue):D152-7 21538280 - Semin Liver Dis. 2011 May;31(2):128-46 22481692 - Arq Gastroenterol. 2012 Jan-Mar;49(1):89-96 17943122 - Nature. 2007 Oct 18;449(7164):851-61 19487572 - Genes Dev. 2009 Jun 1;23(11):1313-26 16258535 - Nature. 2005 Dec 1;438(7068):685-9 18820647 - Nat Genet. 2008 Dec;40(12):1461-5 22356310 - J Dig Dis. 2012 Mar;13(3):153-60 17999673 - Liver Int. 2008 Mar;28(3):385-92 17522677 - Nature. 2007 May 24;447(7143):433-40 16336439 - J Gastroenterol Hepatol. 2005 Dec;20(12):1825-32 20546964 - J Hepatol. 2010 Aug;53(2):335-8 20648474 - Hepatology. 2010 Oct;52(4):1274-80 20370674 - Curr Pharm Des. 2010 Jun;16(17):1952-7 19780876 - J Gastroenterol Hepatol. 2010 Jan;25(1):156-63 16955276 - J Mol Med (Berl). 2006 Nov;84(11):955-65 17565631 - J Gastroenterol Hepatol. 2007 Jun;22(6):788-93 20684021 - Hepatology. 2010 Sep;52(3):894-903 20492333 - J Gastroenterol Hepatol. 2010 Apr;25(4):772-7 22110478 - Exp Diabetes Res. 2012;2012:716425 21988491 - Scand J Immunol. 2012 Feb;75(2):129-41 19208777 - Eur J Endocrinol. 2009 Apr;160(4):593-602 16255080 - Nature. 2005 Oct 27;437(7063):1299-320 19030170 - Hepatology. 2008 Dec;48(6):1810-20 21497744 - Best Pract Res Clin Gastroenterol. 2011 Apr;25(2):269-80 20027673 - World J Gastroenterol. 2009 Dec 28;15(48):6023-7 19651814 - Diabetes. 2009 Nov;58(11):2616-23 17179747 - RNA Biol. 2004 Jul;1(2):106-13 17554300 - Nature. 2007 Jun 7;447(7145):661-78 20460905 - Dig Dis. 2010;28(1):155-61 18081233 - World J Gastroenterol. 2007 Dec 21;13(47):6419-24 19369657 - N Engl J Med. 2009 Apr 23;360(17):1759-68 21623852 - Aliment Pharmacol Ther. 2011 Aug;34(3):274-85 19323962 - Curr Diab Rep. 2009 Apr;9(2):164-71 19844213 - Int J Obes (Lond). 2010 Jan;34(1):190-4 20890895 - Hepatology. 2010 Dec;52(6):1992-2000 20648472 - Hepatology. 2010 Sep;52(3):904-12 17968429 - Br J Cancer. 2007 Nov 5;97(9):1260-5 19818302 - Clin Liver Dis. 2009 Nov;13(4):511-31 17403181 - Liver Int. 2007 May;27(4):423-33 19738004 - J Lipid Res. 2009 Oct;50(10):2111-6 16459310 - Cell Metab. 2006 Feb;3(2):87-98 15202783 - Clin Chem Lab Med. 2004 May;42(5):487-93 20639500 - J Biomol Screen. 2010 Aug;15(7):798-805 19460359 - Biochem Biophys Res Commun. 2009 Aug 7;385(4):492-6 20708005 - Gastroenterology. 2010 Nov;139(5):1567-76, 1576.e1-6 19450891 - J Hepatol. 2009 Jul;51(1):176-86 19224197 - Diabetologia. 2009 Jun;52(6):1056-60 |
References_xml | – reference: 20460905 - Dig Dis. 2010;28(1):155-61 – reference: 17999673 - Liver Int. 2008 Mar;28(3):385-92 – reference: 20648474 - Hepatology. 2010 Oct;52(4):1274-80 – reference: 18820647 - Nat Genet. 2008 Dec;40(12):1461-5 – reference: 18081233 - World J Gastroenterol. 2007 Dec 21;13(47):6419-24 – reference: 17554300 - Nature. 2007 Jun 7;447(7145):661-78 – reference: 22110478 - Exp Diabetes Res. 2012;2012:716425 – reference: 19780876 - J Gastroenterol Hepatol. 2010 Jan;25(1):156-63 – reference: 20027673 - World J Gastroenterol. 2009 Dec 28;15(48):6023-7 – reference: 17968429 - Br J Cancer. 2007 Nov 5;97(9):1260-5 – reference: 22481692 - Arq Gastroenterol. 2012 Jan-Mar;49(1):89-96 – reference: 21988491 - Scand J Immunol. 2012 Feb;75(2):129-41 – reference: 17179747 - RNA Biol. 2004 Jul;1(2):106-13 – reference: 22093607 - Gastroenterol Hepatol. 2012 Jan;35(1):32-41 – reference: 19208777 - Eur J Endocrinol. 2009 Apr;160(4):593-602 – reference: 21037258 - Nucleic Acids Res. 2011 Jan;39(Database issue):D152-7 – reference: 17403181 - Liver Int. 2007 May;27(4):423-33 – reference: 20684021 - Hepatology. 2010 Sep;52(3):894-903 – reference: 20708005 - Gastroenterology. 2010 Nov;139(5):1567-76, 1576.e1-6 – reference: 21538280 - Semin Liver Dis. 2011 May;31(2):128-46 – reference: 19818302 - Clin Liver Dis. 2009 Nov;13(4):511-31 – reference: 20639500 - J Biomol Screen. 2010 Aug;15(7):798-805 – reference: 19844213 - Int J Obes (Lond). 2010 Jan;34(1):190-4 – reference: 21623852 - Aliment Pharmacol Ther. 2011 Aug;34(3):274-85 – reference: 19738004 - J Lipid Res. 2009 Oct;50(10):2111-6 – reference: 18710329 - Metab Syndr Relat Disord. 2008 Sep;6(3):209-14 – reference: 16955276 - J Mol Med (Berl). 2006 Nov;84(11):955-65 – reference: 17943122 - Nature. 2007 Oct 18;449(7164):851-61 – reference: 19460359 - Biochem Biophys Res Commun. 2009 Aug 7;385(4):492-6 – reference: 16336439 - J Gastroenterol Hepatol. 2005 Dec;20(12):1825-32 – reference: 20648472 - Hepatology. 2010 Sep;52(3):904-12 – reference: 16255080 - Nature. 2005 Oct 27;437(7063):1299-320 – reference: 15464424 - Mol Genet Metab. 2004 Sep-Oct;83(1-2):93-102 – reference: 17522677 - Nature. 2007 May 24;447(7143):433-40 – reference: 20890895 - Hepatology. 2010 Dec;52(6):1992-2000 – reference: 19914930 - QJM. 2010 Feb;103(2):71-83 – reference: 15202783 - Clin Chem Lab Med. 2004 May;42(5):487-93 – reference: 20370674 - Curr Pharm Des. 2010 Jun;16(17):1952-7 – reference: 16459310 - Cell Metab. 2006 Feb;3(2):87-98 – reference: 19651814 - Diabetes. 2009 Nov;58(11):2616-23 – reference: 21633658 - World J Gastroenterol. 2011 May 28;17(20):2536-42 – reference: 21497744 - Best Pract Res Clin Gastroenterol. 2011 Apr;25(2):269-80 – reference: 16258535 - Nature. 2005 Dec 1;438(7068):685-9 – reference: 22356310 - J Dig Dis. 2012 Mar;13(3):153-60 – reference: 20546964 - J Hepatol. 2010 Aug;53(2):335-8 – reference: 19450891 - J Hepatol. 2009 Jul;51(1):176-86 – reference: 20473581 - Obes Surg. 2010 Dec;20(12):1698-709 – reference: 20492333 - J Gastroenterol Hepatol. 2010 Apr;25(4):772-7 – reference: 19369657 - N Engl J Med. 2009 Apr 23;360(17):1759-68 – reference: 20803499 - Hepatology. 2010 Oct;52(4):1281-90 – reference: 19323962 - Curr Diab Rep. 2009 Apr;9(2):164-71 – reference: 21381068 - Hepatology. 2011 Jun;53(6):1883-94 – reference: 19224197 - Diabetologia. 2009 Jun;52(6):1056-60 – reference: 17565631 - J Gastroenterol Hepatol. 2007 Jun;22(6):788-93 – reference: 19030170 - Hepatology. 2008 Dec;48(6):1810-20 – reference: 19487572 - Genes Dev. 2009 Jun 1;23(11):1313-26 |
SSID | ssj0023352 |
Score | 2.327275 |
SecondaryResourceType | review_article |
Snippet | Nonalcoholic fatty liver disease (NAFLD) is common worldwide. The importance of genetic and epigen- eric changes in etiology and pathogenesis of NAFLD has been... Nonalcoholic fatty liver disease (NAFLD) is common worldwide. The importance of genetic and epigenetic changes in etiology and pathogenesis of NAFLD has been... |
SourceID | pubmedcentral proquest pubmed crossref chongqing |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 6546 |
SubjectTerms | Adiponectin - genetics Disease Progression DNA Methylation Epigenesis, Genetic Fatty Liver - genetics Fatty Liver - pathology Genetic Variation Genome-Wide Association Study Humans Leptin - genetics MicroRNAs - metabolism mRNA表达水平 Non-alcoholic Fatty Liver Disease Phenotype PPAR gamma - genetics Protein Structure, Tertiary Topic Highlight Tumor Necrosis Factor-alpha - genetics 单核苷酸多态性 肝疾病 肝脏脂肪含量 脂肪肝 表观遗传学 遗传变异 酒精性 |
Title | Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease |
URI | http://lib.cqvip.com/qk/84123X/201245/44400862.html https://www.ncbi.nlm.nih.gov/pubmed/23236228 https://www.proquest.com/docview/1239057798 https://pubmed.ncbi.nlm.nih.gov/PMC3516206 |
Volume | 18 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZQuXBBVLxSHjISFw5JceK8jqgCVRUgDq1oT5YdO9tFsLtsk1bi1zPjRzbZBQl6iXazsa3N98UZj2e-IeR1rUzLG3jSZKpVjFtncZ3VWVwortusrJVqbZTv5-L4jJ-c5-cbZ47NLulU0vz6Y17JbVCFc4ArZsn-B7JDp3ACPgO-cASE4fhPGKNmdBBcNSvU1bRfr2H9a8Nb5r4CSUiJ0psIIRvAgVa4rZALjVrZYREJDNOY7Np4w9UF3Yx0JmbyqlsvUdFz7WSc0Lfw9WQo1fXRhglc9PFF7wnofQvMljlxRWidAw0rQGNt09mOUwymq8R5DrbSsDDqAuB2Cf-7U2wf5CP9hIm5VKOXb5E7-dntiR1FcgCNm2-z5JpVyZznSWg5wnn1wwINRiK8ln3O-VRM-8unoyxnRYoi7XfTEsyt4ODxa3RMQbMb5P5fuJ1tHP5we3DUkfYjoTDH5XIx-wn3Z2rg7KxatoNvR9bM6QNy3y9D6DvHqX1yxyweEuH5RIFPdMMnGvhER3yiwCc64hNdtnTMJ2r5RC2fqOfTI3L24f3p0XHsC3DEDczrXVywpuK6ZlqrtmWtyVvFUyuoxCrFmGZZqqRUugQbspGFqipjwP6VGZg8jcll9pjswdDmKaEZYzJty7wumozrSisluUSl0rdG14aziBwMd1CsnNCK4JzbJXdEDsMtFY2XrscKKt8FLGERGwHYCMBGADYCsYnIm6FF6O3v174KKAmYW3HDTC7Msr8SYNXVsJ4p6yoiTxxqQ28B-oiUEzyHC1C3ffrLYn5p9ds9Aw9u3fIZubd5Wp-TvW7dmxdgG3fqpWXzbzruwUo |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Genetic+and+epigenetic+variants+influencing+the+development+of+nonalcoholic+fatty+liver+disease&rft.jtitle=World+journal+of+gastroenterology+%3A+WJG&rft.au=Li%2C+Yu-Yuan&rft.date=2012-12-07&rft.pub=Baishideng+Publishing+Group+Co.%2C+Limited&rft.issn=1007-9327&rft.volume=18&rft.issue=45&rft.spage=6546&rft.epage=6551&rft_id=info:doi/10.3748%2Fwjg.v18.i45.6546&rft_id=info%3Apmid%2F23236228&rft.externalDocID=PMC3516206 |
thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F84123X%2F84123X.jpg |